Tus-Pharmaceutical Group Co., Ltd. completed the acquisition of Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang.
August 23, 2022
Share
Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) agreed to acquire 100% stake in Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang for CNY 220 million on August 2, 2022. Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) signed the equity transfer agreement to acquire Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang on August 22, 2022. In Guangdong Sinotau Pharmaceutical Co., Ltd. Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. holds 90% and Li Yinqiang holds 10% shares. For the year ended March 31, 2022 Guangdong Sinotau Pharmaceutical Co., Ltd. reported Total assets of CNY 98.28 million and OwnerÃs equity of CNY 36 million. The transaction is approved by the Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) 9th directorate and the target companyÃs shareholdersà meeting already approved this transaction.
Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) completed the acquisition of Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang on August 24, 2022.
Tus Pharmaceutical Group Co Ltd, formerly Tus-Guhan Group Corp Ltd, is principally engaged in the manufacture and sale of pharmaceuticals. The Company provides Chinese medicines, including Chinese healthcare products, medicines for cold treatment and anti hyperlipemia medicines, among others. It also provides western medicine preparations, including clindamycin phosphate for injection, lomefloxacin hydrochloride for injection and levofloxacin lactate for injection, among others. The Company distributes its products in domestic markets.
Tus-Pharmaceutical Group Co., Ltd. completed the acquisition of Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang.